Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
Introduction
Beringer, Engleheim received FDA approval for a novel monoclonal antibody indicated for a condition called generalized postular psoriasis or GPP. The antibody branded Spavigo marks the first IL 36 inhibitor to reach the market. Dr. Karine Bustani is senior vice president, US research sitehead and global head of immunology and respiratory diseases at Beringer.
Transcript
Play full episode
